Islatravir (ISL) is the first nucleoside reverse transcriptase translocation inhibitor (NRTTI) in development for the treatment and prevention of HIV-1 infection. Single doses of ISL as low as 0.5 mg showed robust efficacy in a proof-of-concept (POC) clinical trial and established an IQ (ratio of drug exposure to potency) of 5 for ISL for wild-type HIV-1. In a Ph2 clinical trial (NCT03272347), participants who initiated ISL+doravirine (DOR) in combination with 3TC and switched to ISL+DOR no earlier than Wk 24 had high efficacy at Wk 48 as measured by HIV-1 RNA <50 c/mL. Data through Wk 48 showed that exposure-response was flat, indicating an achievement of maximal efficacy at the ISL doses examined (0.25, 0.75, and 2.25 mg). Modeling and simulation, along with in vitro potency data, were used to select the dose for further clinical development of ISL most appropriate for HIV-1 treatment-naïve, virologically suppressed, and highly-treatment experienced (HTE) populations.
A population pharmacokinetic model for ISL and its active moiety, ISL-triphosphate (ISL-TP), has been developed based on Ph1 and Ph2 data in healthy participants and people living with HIV-1 (PLWH) and used to examine the Ph2 exposure-response relationship. The population pharmacokinetic model was also used to predict the percentage of participants expected to have ISL-TP concentrations sufficient to have antiviral activity against common NRTI-resistant viruses (e.g., M184V, etc.).
Based on an analysis of in vitro potency data, Ph1b POC efficacy, and Ph2 data, a dose of ISL 0.75 mg QD is expected to provide maximal efficacy in treatment-naïve PLWH, and also be highly efficacious in virologically suppressed and HTE participants. Based on the in vitro potency and supported by the POC data for ISL, the expected concentrations of ISL-TP after a single 0.75 mg dose are sufficient to suppress both wild-type virus and HIV-RT resistant variants. ISL-TP accumulates after multiple dosing resulting in higher IQ at steady state. Simulations show that most patients would rapidly surpass the IQ threshold for all common HIV-RT resistant variants.
ISL 0.75 mg QD, in combination with DOR 100 mg QD, is appropriate for further evaluation in a development program consisting of treatment-naïve, virologically-suppressed, and HTE PLWH.